CORRECTED-Amarin Q4 revenue falls 21% on lower sales outside US, Europe

Overview

• Cardiovascular-focussed pharma firm's Q4 revenue fell 21% yr/yr

• Operating expenses decreased 31% due to restructuring

• Company maintained U.S. market leadership for VASCEPA

Outlook

• Amarin aims for positive cash flow throughout 2026

• Company continues to expand European presence through Recordati partnership

• Amarin focuses on maximizing shareholder value and capital management

Result Drivers

• RESTRUCTURING IMPACT - Amarin's Q4 operating expenses decreased 31% due to restructuring efforts, including cost optimization initiatives

• EUROPEAN SALES TRANSITION - Decline in ROW sales due to transition to partnered sales model in Europe, impacting Q4 revenue

• COST SAVINGS - Achieved $31 mln in cost savings from restructuring, contributing to improved financial performance

Company press release: ID:nGNX89tM6f

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Amarin Corporation PLC is $12.00, about 22.7% below its February 24 closing price of $15.52

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.